Gallant Therapeutics
Gallant is developing multiple types of allogeneic or “off-the-shelf” cellular therapies for use in many feline and canine diseases.
The allogeneic therapies are all regulated by the FDA Center for Veterinary Medicine (CVM). Gallant has five INADs open currently, and participates in the FDA CVM Veterinary Innovation Program (VIP) that helps to “fast track” innovative therapies in development.
Gallant uses various cells types depending on the indication being treated incuding, uterine-derived stromal cells, adipose-derived stromal cells and “primed” cell therapies that are treated with various factors to drive them toward specific effectiveness outcomes such as immunomodulation for example.
Gallant Allogeneic Therapy Pipeline
Gallant Scientific Advisory Board
Aaron Hirschhorn
Founder & CEOAs the founder of Gallant, Aaron Hirschhorn brings 20 years of experience operating, advising, and investing in technology companies. Inspired by the impact of regenerative medicine on his own life, Aaron founded Gallant in mid-2018. Previously, Aaron was the Founder and CEO of DogVacay, a consumer marketplace app for dog sitting and dog walking. DogVacay raised $47m from investors including Benchmark Capital and Andreessen Horowitz. The business merged with Rover (Rover.com) in April 2017 to create what is now a $1B pet services company. Outside of Gallant, Aaron is a Venture Partner at Bold Capital and has served as a venture investor with Upfront Ventures. Prior to this, he worked at Monitor Group and Kayne Anderson Capital. He is on several private company boards, a member of YPO, an active angel investor, and was a 2016 finalist for E&Y entrepreneur of the year.Dr. Linda Black, DVM, PhD
Chief Scientific OfficerDr. Black brings more than 15 years of experience in regenerative medicine with extensive experience in development and commercialization of stem cell therapies for pets. From 2016 to 2019, she served as President and Chief Scientific Officer at Medicus Biosciences, a preclinical biotech firm focused on using polymer technologies for localized drug and stem cell delivery. Prior to Medicus, she served as the VP of Product Development for VetStem Biopharma, the first veterinary stem cell company to provide regenerative therapies to horses, dogs and cats. She authored the first peer reviewed publications describing the safety and efficacy of primary adipose derived stem cells in osteoarthritis and muscle injury in dogs. This culminated with starting and leading a product development team to work on the first off-the-shelf stem cell therapies for dogs with osteoarthritis. She was the founder and CEO of SciStem Therapeutics, which focused on delivering off-the-shelf genetically modified stem cells for bone healing in animals and people.Darryl Rawlings
Board MemberDarryl Rawlings has established himself as a leader in medical insurance for cats and dogs. As founder and chief executive officer of Trupanion and founder and member of NAPHIA, Rawlings is setting high standards for a growing industry, expanding public awareness of medical insurance for cats and dogs, and expanding the market across North America. His passion for pet health runs deep. When he was 14, his family dog needed surgery that could have lengthened her life for another 12 years. The cost was beyond his parents’ means and they left the veterinary hospital without her. He vowed that someday pets would have even better medical insurance than people do. And Trupanion has fulfilled that promise with medical insurance for cats and dogs that is remarkably better than most human health insurance. Trupanion covered its first pet in Canada in 2000 and expanded to the United States in 2008. Since expanding to the U.S., Trupanion has established itself as a market leader and now provides medical insurance for cats and dogs in the United States, Canada, and Puerto Rico. In July 2014, Darryl took this a step further, and lead the company through an IPO. Trupanion is publicly traded on NASDAQ. Under his leadership, the company continues to experience consistent growth, with revenue growth in excess of 25% in each of the past 39 quarters. Trupanion now covers more than 500,000 pets. Rawlings is a graduate of the British Columbia Institute of Technology. His family includes his wife Caroline, two sons Sam and Bennett, bulldogs Tristen and Priscilla, cat Halle and bird Q.Richard D. Jennings
Board MemberRichard Jennings is the CEO of California Cryobank Life Sciences and brings a wealth of knowledge and experience in the biomedical and healthcare fields. He joined the company in 2008 and served as the President of the Stem Cell division before being named as CEO. Prior to joining California Cryobank, Richard served as CEO of Mediscan, Administrator of CFHS Holdings (Hospitals), and held leadership positions in R&D and Marketing at Kimberly Clark Corporation. He earned an MBA from Harvard Business School and Bachelor of Science degree in Chemical Engineering. Richard is additionally a Board Member of Palisades Country Estates and Village School. He supports various fund raising efforts including the Leukemia & Lymphoma Society.Art Antin
AdvisorArthur J. Antin is the co-founder of VCA, Inc., the largest family of animal care providers nationwide. Since its establishment in 1986, VCA has expanded its operations to include 923 hospitals in 46 U.S. states and five Canadian provinces. It also provides diagnostic services to more than 17,000 independent hospitals, supplies high-tech imaging, and now offers doggy day care and boarding at over 168 locations. Antin has served as VCA’s Chief Operating Officer, Senior Vice President, Secretary and Director. While the company was sold to Mars, Inc. in 2017, Antin continues with VCA as a Senior Advisor working on the company’s expansion into emerging markets in Brazil and Japan. Prior to VCA, Mr. Antin worked as an educator for eight years in Yonkers, NY. He then served as Director of Marketing/Investor Relations of AlternaCare Corporation, where he developed and implemented marketing strategies for a network of publicly traded outpatient surgical centers. Antin received his AA from Bronx Community College in 1967, BA from City College in 1969, MA in Community Health from New York University in 1973 and Certificate in Computer Programming from Columbia University in 1982. Today, Antin serves on the Board of Directors of the Boys and Girls Club of Santa Monica and Western University in Pomona, CA. He lives with his wife, Pat, in Santa Monica, CA, where he enjoys playing golf and cycling.Dr. David Haworth DVM, PhD
AdvisorDavid Haworth is former President of PetSmart Charities in the US and Canada. An independent non-profit, strategic grant-making organization, PetSmart Charities seeks to end pet homelessness by supporting partner organizations and programs that help find loving homes for all pets and celebrates the bond between people and animals. Dr. Haworth was formerly President & CEO at Morris Animal Foundation, Director of Global Alliances within the Business Development group at Pfizer Animal Health (now Zoetis, Inc.), and before that a Director in Pfizer Animal Health's Research & Development division. Prior to joining Pfizer Animal Health, he was an associate veterinarian at a small animal and emergency clinic in Washington State. Dr. Haworth received his bachelor of science in biology from the College of William & Mary and his doctor of veterinary medicine and doctorate of philosophy from Colorado State University. He also completed a postdoctoral fellowship at Colorado State University's Flint Animal Cancer Center.
Ready to learn more?
Explore our stem cell banking process or chat with one of our pet-loving experts.